Skip to main content

Treatment Clinical Trials for Liver Cancer

Review the liver cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 122

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Status: Active
Location: 5 locations
Tislelizumab Before and After Radiation Therapy for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Hypofractionated Radiotherapy Followed by Durvalumab with or without Tremelimumab for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Status: Active
Location: 2 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
Zanzalintinib with Durvalumab plus Tremelimumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma, The ZENOBIA Trial
Status: Active
Location: 2 locations
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Status: Active
Location: 2 locations
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Status: Active
Location: 2 locations
A Study of ZW251 in Participants With Advanced Solid Tumors
Status: Active
Location: 3 locations
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor with Liver Metastatic Disease
Status: Active
Location: 2 locations
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA
Status: Active
Location: MedStar Georgetown University Hospital, Washington, District of Columbia
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Regorafenib and Yttrium-90 Transarterial Radioembolization for the Treatment of Unresectable Hepatocellular Cancer
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tremelimumab and Durvalumab for the Treatment of Advanced Liver Cell Cancer in Patients with Child-Pugh-B Cirrhosis
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Sacituzumab Govitecan for the Treatment for Patients with Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Tertiary and Community Care Models for the Administration of Hepatic Artery Infusion Chemotherapy in Patients with Unresectable or Resectable Colorectal Liver Metastases and Unresectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky